Reported Early Stage Prostate Cancer Incidence Again Decreased

MedicalResearch.com Interview with:

Dr. Ahmedin Jemal, DVM, PhD Vice President, Surveillance and Health Services Research American Cancer Societ

Dr. Ahmedin Jemal

Dr. Ahmedin Jemal, DVM, PhD
Vice President, Surveillance and Health Services Research
American Cancer Society

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: We previously showed large decrease in early stage prostate cancer incidence rates from 2011 to 2012 in men 50 years and older following the US Preventive services Task Force recommendation against routine prostate-specific antigen testing in 2011. In this paper, we examined whether the decrease in early stage incidence persisted through 2013.

We found that early stage prostate cancer incidence rates in men age 50 and older decreased from 2012 to 2013, although the decrease (6%) was lower compared to the decrease from 2011-2012 (19%). In contrast, rates for distant stage disease between 2012 and 2013 remained unchanged.

MedicalResearch.com: What should readers take away from your report?

Response: Early stage prostate cancer rates continue to fall following the USPSTF recommendation against PSA testing, albeit at a slower pace than the previous year.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Response: Long-term monitoring is needed to ascertain whether the continued decrease in early stage prostate cancer incidence rate will eventually lead to increased diagnosis of distant stage disease and mortality because of the slow-growing nature of this cancer.

MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.

Citation:

Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.

More Medical Research Interviews on MedicalResearch.com

[wysija_form id=”5″]